Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to creating and marketing highly specific diagnostic tools that leverage the immune system, as well as therapeutic agents also based on immune principles. Its operations are divided into two primary divisions: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, designed to selectively bind to the CD206 mannose receptor found on activated macrophages.